Maiuri Francesco, Mariniello Giuseppe, Somma Teresa, Guadagno Elia, Corvino Sergio, Pagano Serena, Orlando Valentina, Del Basso De Caro Marialaura
Neurosurgical Clinic, Department of Neurosciences and Reproductive and Odontostomatological Sciences, University "Federico II", Naples, Italy.
Section of Pathology, Department of Advanced Biomorphological Sciences, University "Federico II", Naples, Italy.
Front Oncol. 2020 Dec 11;10:556701. doi: 10.3389/fonc.2020.556701. eCollection 2020.
Several epidemiological and pathological findings suggest that the female sex hormones may influence the development of meningiomas. However, the role of pregnancy, oral contraceptives, and fertilization therapies is still controversial.
From the surgical series of 354 patients with meningiomas operated between 2006 and 2019, the group of 72 premenopausal women was separately considered. The tumor location, WHO grade, Ki67-labeling index (LI), progesterone receptor (PR) expression, and histological types were studied in premenopausal women with and without hormone-related conditions were compared.
In this premenopausal group, 24 patients had hormone-related conditions, including use of oral contraceptives in 16, intrauterine fertilization in one, pregnancy in three, and tumors of the female reproductive system in four. The group of patients with hormone-related conditions, as compared to that with no hormone related conditions, showed slightly lower median age (38 43 years) and no significant difference of meningioma location WHO grade, Ki 67-Li, PR expression and histological type. The clinical onset during pregnancy in three patients and tumor growth during contraceptive progesterone therapy in two others were evidenced.
The biological behavior of meningiomas and their pathological findings, including PR expression, are not correlated with the different hormone related conditions in premenopausal female patients. Contraceptives and fertilization therapies, mainly with progesterone, should be avoided in patients with meningiomas.
多项流行病学和病理学研究结果表明,女性性激素可能影响脑膜瘤的发生发展。然而,妊娠、口服避孕药及辅助生殖技术的作用仍存在争议。
在2006年至2019年间接受手术的354例脑膜瘤患者的手术病例系列中,单独考虑72例绝经前女性患者。研究了绝经前有或无激素相关疾病的女性患者的肿瘤位置、世界卫生组织(WHO)分级、Ki67标记指数(LI)、孕激素受体(PR)表达及组织学类型,并进行比较。
在该绝经前组中,24例患者有激素相关疾病,包括16例口服避孕药使用者、1例接受宫内受精者、3例妊娠者及4例患有女性生殖系统肿瘤者。与无激素相关疾病的患者组相比,有激素相关疾病的患者组中位年龄略低(38对43岁),脑膜瘤位置、WHO分级、Ki67-LI、PR表达及组织学类型无显著差异。有3例患者在孕期发病,另有2例在避孕用孕激素治疗期间肿瘤生长。
绝经前女性脑膜瘤的生物学行为及其病理表现,包括PR表达,与不同激素相关疾病无关。脑膜瘤患者应避免使用避孕药及辅助生殖技术,主要是含孕激素的治疗。